Multicenter phase 3 study of first-line furmonertinib versus gefitinib for advanced EGFR mutation-positive NSCLC

Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR TKI. The multicenter phase 3 FURLONG study in China evaluated first-line furmonertinib versus gefitinib for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. The median progression-free survival was 20.8 months (95% CI 17.8-23.5) with furmonertinib versus 11.1 months (9.7-12.5) with gefitinib (HR 0.44; p<0.0001). Grade 3 or higher TRAEs occurred in 11% of patients with furmonertinib and 18% of patients with gefitinib. The authors conclude that furmonertinib had superior efficacy compared with gefitinib, with an acceptable safety profile.